Clinical and Pathological Analysis of Eleven Adult Patients with Inflammatory Myofibroblastic Tumor.

Xin Liu,Xiaowei Zhang,Huijie Wang,Chunmeng Wang,Yong Chen,Jian Wang,Zhiguo Luo
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.11545
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:11545 Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy which occurs primarily in children and adolescents. Complete surgical resection is the major treatment, and conventional chemotherapy and radiotherapy are usually invalid. In this study, we retrospectively analyzed the clinical and pathological features of eleven patients with adult IMT. Methods: A total of eleven patients with adult IMT were enrolled into this study between February 2013 and November 2017. The clinical, pathological data, treatment and prognosis were analyzed. Results: Among the eleven patients with adult IMT, five patients were male (45%), six patients were female (55%), and the median age was 39 (24-74 years). The primary tumor was located in two patients (18%) in the lung and two cases (18%) in the retroperitoneum, and seven cases (64%) in the abdominopelvic region. Four cases were abdominal epithelioid inflammatory myofibroblastic sarcoma. The positive rate of anaplastic lymphoma kinase (ALK) immunohistochemical expression was 82% (9/11), and the positive rate of ALK translocation was 86% (6/7). Seven patients with ALK-positive advanced disease received the treatment of ALK inhibitor crizotinib, the response rate was 86%, and the median progression free survival (PFS) was 20.8 months (95% confidence interval: 7.6 months-34.0 months). Two patients were treated with the more potent ALK inhibitor ceritinib after progression of disease on crizotinib and both of them showed significant and durable partial responses. Conclusions: The treatment of crizotinib in adult patients with ALK-positive advanced IMT resulted in a very high response rate and a long-term PFS, and the patients still responded to the next generation of ALK inhibitor after the failure of crizotinib in our study, which suggested that ALK signaling pathway may play an important role in the development of adult IMT. Further studies are warranted to clarify the effects of ALK signaling pathway and the mechanism of ALK inhibitor resistance in adult patients with IMT.
What problem does this paper attempt to address?